2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157702
    1-Heptadecenoyl-2-OH-sn-glycero-3-phosphoethanolamine 1246298-09-8 98%
    1-Heptadecenoyl-2-OH-sn-glycero-3-phosphoethanolamine is an ester product.
    1-Heptadecenoyl-2-OH-sn-glycero-3-phosphoethanolamine
  • HY-157705
    18:1 PI(3,5)P2 triammonium 799268-55-6 98%
    18:1 PI(3,5)P2 (triammonium) is a phosphoinositide. Phosphoinositides (PI) are similar to other phospholipids, but the head group is the cyclic myo-inositol.
    18:1 PI(3,5)P2 triammonium
  • HY-157706
    PI(3,4)P2 (18:1) ammonium salt 799268-54-5 98%
    PI(3,4)P2 (18:1) ammonium salt is a phosphatidylinositol 3 kinase (PI3K) activator. PI(3,4)P2 (18:1) ammonium salt is a polyphosphorylated phosphatidylinositol that promotes the activation of AKT (protein kinase B) by activating PI3K, which affects cell metabolism, growth and survival. PI(3,4)P2 (18:1) ammonium salt is also involved in regulating dynamic changes in the cytoskeleton, affecting cell morphology and movement. PI(3,4)P2 (18:1) ammonium salt can be used in research on the development of cancer, diabetes and cardiovascular disease.
    PI(3,4)P2 (18:1) ammonium salt
  • HY-157709
    18:1 PI ammonium 799268-53-4 98%
    18:1 PI (ammonium) is a phosphoinositide. Phosphoinositides (PI) are similar to other phospholipids, but the head group is the cyclic myo-inositol.
    18:1 PI ammonium
  • HY-157711
    08:0 PG sodium 322647-21-2 98%
    08:0 PG sodium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    08:0 PG sodium
  • HY-157713
    diC8PI(3,5)P2 triammonium 852043-36-8 98%
    diC8PI(3,5)P2 (08:0 PI(3,5)P2) triammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    diC8PI(3,5)P2 triammonium
  • HY-157731
    α-Laurodimyristin 60138-12-7 98%
    α-Laurodimyristin is a triacylglycerol that contains myristic acid and lauric acid.
    α-Laurodimyristin
  • HY-15790R
    Elobixibat (Standard) 439087-18-0 98%
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat (Standard)
  • HY-15790S
    Elobixibat-d5 98%
    Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly.
    Elobixibat-d5
  • HY-158200
    5-Aminoallyl-dUTP 116840-18-7
    5-Aminoallyl-dUTP (5-Aminoallyl 2'-deoxyuridine 5'-triphosphate) is a monomeric raw material that can be used for nucleic acid synthesis.
    5-Aminoallyl-dUTP
  • HY-15848R
    AdipoRon (Standard) 924416-43-3 98%
    AdipoRon (Standard) is the analytical standard of AdipoRon. This product is intended for research and analytical applications. AdipoRon is an orally active adiponectin receptor (AdipoR) agonist, binding to AdipoR1 and AdipoR2 with Kds of 1.8 and 3.1 μM, respectively.
    AdipoRon (Standard)
  • HY-158572
    PtdIns-(4,5)-P2 (1,2-dipalmitoyl) trisodium 1628353-01-4 98%
    PtdIns-(4,5)-P2 (1,2-dipalmitoyl) (trisodium) is a phosphoinositide. Phosphoinositides (PI) are similar to other phospholipids, but the head group is the cyclic myo-inositol.
    PtdIns-(4,5)-P2 (1,2-dipalmitoyl) trisodium
  • HY-15859R
    Atglistatin (Standard) 1469924-27-3 98%
    Atglistatin (Standard) is the analytical standard of Atglistatin. This product is intended for research and analytical applications. Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.
    Atglistatin (Standard)
  • HY-158656
    3-Keto sphinganine (d6:0) hydrochloride 1824544-52-6 98%
    3-Keto sphinganine (d6:0) (3-Keto-C6-dihydrosphingosine) hydrochloride, an ester product, is a short-chain analog of 3-keto sphinganine. 3-keto sphinganine provokes the accumulation of dihydroshingolipids and induces autophagy in cancer cells.
    3-Keto sphinganine (d6:0) hydrochloride
  • HY-158825
    Cepadacursen sodium 2252375-14-5
    Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).
    Cepadacursen sodium
  • HY-158827
    AZD8233 2604215-74-7
    AZD8233, a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. AZD8233 increases the available LDL receptors by reducing PCSK9 levels, thereby clearing LDL from the blood and decreasing LDL-C levels.
    AZD8233
  • HY-158912
    1-Oleoyl-3-arachidoyl-rac-glycerol 1427086-85-8 98%
    1-Oleoyl-3-arachidoyl-rac-glycerol (DG(18:1/0:0/20:0)) is a diacylglycerol that contains Oleic acid (HY-N1446) and Arachidic acid (HY-W004260).
    1-Oleoyl-3-arachidoyl-rac-glycerol
  • HY-158945
    1,3-Dipalmitoleoyl-2-11(Z)-octadecenoyl glycerol 2348469-98-5 98%
    1,3-Dipalmitoleoyl-2-11(Z)-octadecenoyl glycerol (1,3-Palmitolein-2-vaccenate) is a triacylglycerol that contains Palmitoleic acid (HY-W011873) and cis-Vaccenic acid (HY-113427A).
    1,3-Dipalmitoleoyl-2-11(Z)-octadecenoyl glycerol
  • HY-158946
    1,2-Dielaidoyl-3-linoleoyl-rac-glycerol 2692623-11-1 98%
    1,2-Dielaidoyl-3-linoleoyl-rac-glycerol (1,2-Dielaidin-3-linolein) is a triacylglycerol that contains Elaidic acid (HY-113016) and Linoleic acid (HY-N0729).
    1,2-Dielaidoyl-3-linoleoyl-rac-glycerol
  • HY-158948
    1-Palmitoyl-2-11(Z)-octadecenoyl-3-butyroyl-rac-glycerol 2692623-15-5 98%
    1-Palmitoyl-2-11(Z)-octadecenoyl-3-butyroyl-rac-glycerol (1-Palmitin-2-vaccenate-3-butyrin) is a triacylglycerol that contains Palmitic acid (HY-N0830), cis-Vaccenic acid (HY-113427A), and Butyric acid (HY-B0350).
    1-Palmitoyl-2-11(Z)-octadecenoyl-3-butyroyl-rac-glycerol
Cat. No. Product Name / Synonyms Application Reactivity